Keyphrases
Epidermal Growth Factor Receptor
100%
Non-small Cell Lung Cancer Cells
100%
Gefitinib Resistance
100%
Gefitinib
57%
Non-small Cell Lung Cancer (NSCLC)
42%
Gefitinib-resistant
42%
L858R/T790M
42%
Downstream Signaling
28%
Double mutant
28%
Resistant Cell Lines
28%
Induced Apoptosis
14%
Tumor Growth
14%
Signaling Pathway
14%
Phosphorylation
14%
Tumor Size
14%
Acquired Resistance
14%
Cancer Tumor
14%
Non-small Cell Lung Cancer Patients
14%
Clinical Treatment
14%
Cancer Cell Growth
14%
Kinase Activity
14%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
14%
Phosphorylation Reaction
14%
Cell Colony
14%
Receptor Phosphorylation
14%
Colony Formation
14%
ATP-competitive
14%
ERK2
14%
Lung Cancer Cells
14%
Double mutation
14%
Patient-derived Xenograft
14%
Xenograft Mouse Model
14%
SCID Mouse Model
14%
L858R
14%
Mutant Epidermal Growth Factor Receptor
14%
Medicine and Dentistry
Cancer Cell
100%
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
100%
Gefitinib
100%
Xenograft
25%
Lung Cancer
12%
Phosphotransferase
12%
Tumor Progression
12%
Cancer Growth
12%
Cell Signaling Pathway
12%
Programmed Cell Death
12%
Mitogen Activated Protein Kinase 3
12%
Colony Formation
12%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Resistant Cell Line
12%
Tumor
12%
Gefitinib-Resistant Cell Line
12%
Cell Culture
12%
Adenosine Triphosphate
12%
SCID Mouse
12%
Protein Kinase B
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Gefitinib
100%
Epidermal Growth Factor Receptor
88%
Mouse Model
22%
SCID Mouse
11%
Lung Cancer
11%
Tumor Growth
11%
Cancer Growth
11%
Phosphotransferase
11%
Mitogen Activated Protein Kinase 3
11%
Epidermal Growth Factor Receptor Kinase Inhibitor
11%
Adenosine Triphosphate
11%